Platelet reactivity unit (PRU) in patients undergoing elective PCI: Rethinking the optimal cut point

نویسندگان

  • Hassan Sharifi
  • Valiollah Habibi
  • Amir Emami Zeydi
چکیده

High residual platelet reactivity (PR) in patients on clopidogrel therapy is associated with thrombotic events after percutaneous coronary intervention (PCI) with drug-eluting stents. It is well documented that determining an optimal PR cut-off point helps to better predict major adverse cardiovascular events (MACE). In addition, determining the optimal PR cut-off point helps to sufficiently suppress the platelet aggregation to prevent thrombotic events after PCI. However, the measurements of platelet function in patients on clopidogrel therapy have indicated wide variability in P2Y12 inhibition level (1), which is relatively explicated by genetic polymorphisms encoding CYP2C19 as well as the hepatic enzyme CYP450. In this regard, several studies have selected different PR cut-off points to identify high-risk patients. For example, in a study with 660 patients, Nakamura et al. (2) found that the optimal platelet reactivity unit (PRU) cut-off point for preventing MACE after PCI is 262. In another study by Marcucci et al. (3), the PRU cut-off point of 240 was shown to be predictive of MACE. Koltowski et al. (4) considered the PRU cut-off point of 208 PRU (measured using the VerifyNow P2Y12 assay) as inadequate platelet inhibition. Much inconsistency exists in the literature concerning the selection of optimal PR cut-off point in patients on clopidogrel therapy undergoing elective PCI. It important that the optimal PRU cut-off point in patients treated with clopidogrel has not been discussed in the 2011 American College of Cardiology (ACC) / American Heart Association Guideline for PCI (5). Therefore, selecting the optimal PRU cut-off point warrants further investigations. The optimal PRU cut-off point should be studied and integrated in the current clinical practice guidelines so that it becomes a standard of practice for PCI. Hassan Sharifi1,2, Valiollah Habibi3, Amir Emami Zeydi2 Department of 1Medical-Surgical Nursing, School of Nursing and Midwifery, Iranshahr University of Medical Sciences; Iranshahr-Iran Department of Student Research Committee 2Student Research Committee, Department of Medical-Surgical Nursing, School of Nursing and Midwifery, Mashhad University of Medical Sciences; Mashhad-Iran Department of 3Cardiac Surgery, Faculty of Medicine, Mazandaran University of Medical Sciences; Sari-Iran

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.

AIMS The aim of this study was to determine whether platelet reactivity on clopidogrel therapy, as measured by a point-of-care platelet function assay, is associated with thrombotic events after percutaneous coronary intervention (PCI) with drug-eluting stents (DESs). METHODS AND RESULTS Platelet reactivity on clopidogrel (post-treatment reactivity) was measured with the VerifyNow P2Y12 assay...

متن کامل

Optimal aNtiplatelet pharmacotherapy guided by bedSIDE genetic or functional TESTing in elective PCI patients: A pilot study: ONSIDE TEST pilot.

BACKGROUND Dual antiplatelet therapy (DAPT) is recommended after elective percutaneous coronary intervention (PCI) in stable coronary artery disease (SCAD) patients; however, still one-third of patients do not obtain adequate platelet inhibition that may result in increased cardiovascular risk. The aim of the ONSIDE TEST study is to evaluate the clinical impact of point-of-care genotyping- and ...

متن کامل

The optimal threshold of high post-treatment platelet reactivity could be defined by a point-of-care VerifyNow P2Y12 assay

We read with great interest the study by Price et al., which verifies that high post-treatment platelet reactivity (HPPR) measured with a point-of-care VerifyNow assay (Accumetrics Inc., San Diego, CA, USA) is associated with post-discharge events after percutaneous coronary intervention (PCI) with drug-eluting stent (DES), including stent thrombosis. To the best of our knowledge, this is the f...

متن کامل

Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.

AIMS The Stent Thrombosis In Belgium (STIB) trial aimed to determine whether assessing platelet reactivity (PR) in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention (PCI) could predict the risk of ischaemic complications and adverse clinical events up to 30 days post PCI. METHODS AND RESULTS PR before intervention was determined in 891 patient...

متن کامل

Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials

BACKGROUND Cilostazol overcomes high on-treatment platelet reactivity (HTPR) and reduces adverse cardiovascular (CV) outcomes after percutaneous coronary intervention (PCI). However, the role for triple antiplatelet therapy (TAPT) with cilostazol in addition to aspirin and clopidogrel after PCI is not well defined. METHODS We conducted a MEDLINE/EMBASE/CENTRAL search for randomised trials, un...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 18  شماره 

صفحات  -

تاریخ انتشار 2017